Core Viewpoint - The article highlights the successful hosting of multiple global medical conferences, focusing on ophthalmology, orthopedics, cardiovascular health, and aesthetic technology, showcasing advancements and discussions in the medical equipment sector [1]. Group 1: Conference Overview - The first Global Ophthalmology Conference, Global Orthopedics Conference, Global Cardiovascular Conference, and Global Aesthetic Technology Conference were held, emphasizing the importance of innovation in medical devices and healthcare [1]. Group 2: Conference Agenda - The agenda included various presentations on topics such as hospital product admission processes, high-quality development of innovative medical devices, pricing requirements in hospitals, and the significance of market access planning [2]. - Notable speakers included leaders from the China Medical Equipment Association and experts from various hospitals, providing insights into the medical equipment industry's regulatory and operational frameworks [2]. Group 3: Registration Information - Participation in the conferences required a fee of 1200 yuan per person, with limited spots available, encouraging early registration [4].

Core Viewpoint - The article highlights the challenges faced by patients with myasthenia gravis, a rare autoimmune disease, including misdiagnosis, treatment difficulties, and the need for better healthcare support and awareness [1][4][11]. Group 1: Patient Challenges - Patients with myasthenia gravis often experience symptoms such as sudden weakness, drooping eyelids, and difficulty swallowing, leading to misdiagnosis as psychological issues or other conditions [3][4]. - The prevalence of myasthenia gravis is approximately 7.4 per million people, translating to around 650,000 patients in China due to the large population [4][7]. - Many patients report being misdiagnosed for years, which delays appropriate treatment and exacerbates their condition [3][4]. Group 2: Treatment and Healthcare Support - Current treatments for myasthenia gravis include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but many essential medications are not covered by insurance, leading to high out-of-pocket costs [7][8]. - The new national medical insurance drug list, effective January 1, 2024, includes two medications for myasthenia gravis, but patients still face significant financial burdens for ongoing and crisis treatments [7][8]. - Experts suggest that myasthenia gravis should be included in outpatient chronic disease categories to improve reimbursement rates and access to necessary medications [8][9]. Group 3: Psychological and Social Aspects - The psychological impact of myasthenia gravis is significant, with many patients facing discrimination and social stigma due to visible symptoms like drooping eyelids [11]. - A study indicated that 17.1% of surveyed patients experienced discrimination affecting their work and study opportunities, highlighting the need for greater societal awareness and support [11]. - Mental health support is emphasized as a crucial component of treatment, alongside physical health interventions [11].